Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep

Varegacestat, a gamma secretase inhibitor, significantly improved progression-free survival while also meeting all key secondary endpoints in the pivotal RINGSIDE trial. Immunome is planning an FDA application for the second quarter of 2026.